Is KALA BIO, Inc. (KALA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 12.7% / 30% | 20.2% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 12.7% / 33% | 20.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 58.1% / 33% | 92.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 12.7% / 33% | 20.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 58.1% / 33% | 92.2% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -65.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$29M |
| Free Cash Flow | -$30M |
| Total Debt | $32M |
| Current Ratio | 0.7 |
| Total Assets | $55M |
Price & Trading
| Last Close | $0.20 |
| 50-Day MA | $0.39 |
| 200-Day MA | $3.87 |
| Avg Volume | 7.1M |
| Beta | -2.4 |
|
52-Week Range
$0.16
| |
About KALA BIO, Inc. (KALA)
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is KALA BIO, Inc. (KALA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), KALA BIO, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is KALA BIO, Inc.'s debt ratio?
KALA BIO, Inc.'s debt ratio is 12.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 58.1%.
What are KALA BIO, Inc.'s key financial metrics?
KALA BIO, Inc. has a market capitalization of $160M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.